688319.SH
Chengdu Olymvax Biopharmaceuticals, Inc.
SSE · Healthcare · Biotechnology · CN
CNY 25.91
+2.70%Year over year
Reported trailing growth
- Revenue
- +27.9%
- EBITDA
- —
- EBIT
- +65.1%
- EPS
- +42.8%
- Free cash flow
- +100.2%
- Operating cash flow
- +222.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.8%
- EBITDA
- -0.3%
- EBIT
- -9.5%
- Net income
- -5.7%
- EPS
- -5.8%
- Free cash flow
- +103.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026